1-[2-(4-tert-butylphenoxy)ethyl]piperazine | 401505-21-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[2-(4-tert-butylphenoxy)ethyl]piperazine
• CAS: 401505-21-3
• 化学式: C₁₆H₂₆N₂O
• 分子量: 262.395
• InChiKey: NFUZVKXDOKMQJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-氯乙酰胺基)噻唑 、 1-[2-(4-tert-butylphenoxy)ethyl]piperazine 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 以46.85%的产率得到N-(thiazol-2-yl)-2-(4-(2-(4-(tert-butyl)phenoxy)ethyl)piperazin-1-yl)acetamide
  参考文献：
  名称：

  发现1-芳氧基乙基哌嗪衍生物作为Kv1.5钾通道抑制剂（第一部分）

  摘要：

  Kv1.5钾通道是一种治疗房颤（AF）的有效且安全的治疗靶标，它是威胁人类的最常见心律不齐。本文中，通过从内部数据库中修改命中化合物7k，合成了48种衍生物，以通过全细胞膜片钳技术测定其Kv1.5抑制作用。选择了六种显示出比阳性化合物决奈达隆更好的效价的化合物用于其类药物性质的下一个评估。化合物8显示出平衡的溶解度和渗透性。它还显示出可接受的药效学特征，急性毒性非常低。考虑到所有这些数据，化合物8 可以作为开发用于治疗AF的新型治疗剂的有希望的先导。

  DOI：

  10.1016/j.ejmech.2014.03.075
• 作为产物：
  描述：

  benzyl 4-(2-hydroxyethyl)piperazine-1-carboxylate 在 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.83h， 生成 1-[2-(4-tert-butylphenoxy)ethyl]piperazine
  参考文献：
  名称：

  [EN] 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION
  [FR] OXINDOLES 3,3-DI-SUBSTITUÉS EN TANT QU'INHIBITEURS DE L'INITIATION DE LA TRADUCTION

  摘要：

  提供了用于抑制翻译的组合物和方法。描述了使用二苯氧吲哚化合物治疗（1）细胞增殖性疾病，（2）非增殖性退行性疾病，（3）病毒感染和/或（4）与病毒感染相关的疾病的组合物、方法和试剂盒。

  公开号：

  WO2014047437A1

文献信息

• Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070173519A1

  公开（公告）日：2007-07-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  由式（1）表示的吡唑吡嘧啶衍生物及其药用盐对MAPKAP-K2表现出优异的抑制活性。因此，含有该化合物作为活性成分的药物预计对治疗由MAPKAP-K2介导的疾病，如炎症性疾病、自身免疫疾病、破坏性骨病、癌症和/或肿瘤生长等方面具有有效性。
• Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof
  申请人：UNOKI Gen

  公开号：US20090054472A1

  公开（公告）日：2009-02-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  式（1）所表示的吡唑并嘧啶衍生物及其药学上可接受的盐，表现出对MAPKAP-K2的优异抑制活性。因此，含有该化合物作为活性成分的药物预计将对由MAPKAP-K2介导的疾病具有治疗作用，例如，炎症性疾病、自身免疫性疾病、破坏性骨病、癌症和/或肿瘤生长。
• 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation
  申请人：President and Fellows of Harvard College

  公开号：US20160106711A1

  公开（公告）日：2016-04-21

  Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using diaryloxindole compounds are described.

  本发明提供了用于抑制翻译的组合物和方法。本发明还提供了使用二苯并呋喃衍生物治疗（1）细胞增殖性疾病，（2）非增殖性退行性疾病，（3）病毒感染和/或（4）与病毒感染相关的疾病的组合物、方法和试剂盒。
• Synthesis and SAR study of novel 3,3-diphenyl-1,3-dihydroindol-2-one derivatives as potent eIF2·GTP·Met-tRNAiMet ternary complex inhibitors
  作者：Séverine Denoyelle、Ting Chen、Hongwei Yang、Limo Chen、Yingzhen Zhang、José A. Halperin、Bertal H. Aktas、Michael Chorev

  DOI：10.1016/j.ejmech.2013.08.030

  日期：2013.11

  The growing recognition of inhibition of translation initiation as a new and promising paradigm for mechanism-based anti-cancer therapeutics is driving the development of potent, specific, and druggable inhibitors. The 3,3-diaryloxindoles were recently reported as potential inhibitors of the elF2.GTP.MettRNAlviet ternary complex assembly and 345-tert-butyl-2-hydroxypheny1}-3-phenyl-1,3-dihydro-2Hindol-2-one #1181 was identified as the prototypic agent of this chemotype. Herein, we report our continuous effort to further develop this chemotype by exploring the structural latitude toward different polar and hydrophobic substitutions. Many of the novel compounds are more potent than the parent compound in the dual luciferase ternary complex reporter assay, activate downstream effectors of reduced ternary complex abundance, and inhibit cancer cell proliferation in the low uM range. Moreover, some of these compounds are decorated with substituents that are known to endow favorable physicochemical properties and as such are good candidates for evaluation in animal models of human cancer. (C) 2013 Elsevier Masson SAS. All rights reserved.
• US7473694B2
  申请人：——

  公开号：US7473694B2

  公开（公告）日：2009-01-06